Drug intelligence / Profile preview

Valtorcitabine

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

Valtorcitabine is an investigational antiviral drug candidate that was developed as a nucleoside analogue for the treatment of hepatitis B virus (HBV) infection. It is a prodrug of 2'-deoxyguanosine, designed to inhibit HBV DNA polymerase by acting as a chain terminator during viral DNA synthesis. Valtorcitabine was under development primarily by Idenix Pharmaceuticals for chronic hepatitis B but its clinical development was discontinued and it has not been approved or marketed.

Targets

HBV Pol (Hepatitis B virus polymerase)

Beyond the preview

Go deeper on Valtorcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Valtorcitabine.

Explore the full profile